ClinicalTrials.gg
RecruitingNCT04894825Updated Nov 27, 2023

Safety, Tolerability and Pharmacokinetic Profile of M108 Monoclonal Antibody in Patients With Advanced Unresectable Solid Tumors in China

A Phase 1 interventional study of M108 and M108 in Advanced Unresectable Solid Tumors, sponsored by FutureGen Biopharmaceutical (Beijing) Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-11-27.

Sponsored by FutureGen Biopharmaceutical (Beijing) Co., Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 3 months ago, but the record still lists the study as recruiting.
  • Started Jun 2021; still recruiting 5 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
152
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

M108 is a monoclonal antibody specific for gastric and gastroesophageal adenocarcinomas. The aim of this phase I study is to establish safety and Tolerability of different Dosage regimen in patients With Advanced Unresectable Solid Tumors in China.

02

Conditions studied

  • Advanced Unresectable Solid Tumors
03

In context

Lead sponsor

FutureGen Biopharmaceutical (Beijing) Co., Ltd is the lead sponsor of 6 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written .
  2. Advanced Unresectable solid tumors proven by histology
  3. At least 1 measurable site of the disease according 1.1 criteria
  4. performance status (PS) 0-1
  5. > 3 months
  6. Age ≥ 18 years and ≤75 years
  7. Adequate haematological function; ≥1.5 x 109/L; white blood cell count ≥3.0 x 109/L; ≥100 x 109/L; ≥9 g/dL.
  8. Adequate coagulation function; ( INR) ≤ 1.5 x (ULN), or activated partial thromboplastin time (APTT) ≤ 1.5 x ULN.
  9. Adequate hepatic function; ≤1.5 x ULN, (AST), and alanine aminotransferase (ALT) ≤2.5 x ULN.
  10. Adequate renal function; creatinine ≤1.5 x ULN, or reatinine clearance rate ≥60 mL/minute calculated.

Exclusion criteria

Exclusion Criteria:

  1. Previous received or planned to be vaccinated with 2019-nCoV vaccine or other vaccines within 3 months prior to the start of study treatment or during the study or within 3 months after the end of the study;
  2. Previous radiotherapy within 4 weeks prior to the start of study treatment. (if palliative radiotherapy was given to bone side peripherally and the patient recovered from acute toxicity was allowed).
  3. Previous anti-tumor therapy within 4 weeks prior to the start of study treatment.
  4. Previous major operation within 8 weeks prior to the start of study treatment.
  5. Prior severe allergic reaction or intolerance to a monoclonal antibody, including humanised or chimeric antibodies.
  6. Symptomatic cerebral metastases.
  7. Uncontrolled or severe illness.
  8. Known infection or known symptomatic hepatitis
  9. Other disease which may have adversely affected the safe delivery of treatment within this study
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
152 participants (estimated)

Study arms

  • Experimental
    Dose Escalation Cohort

    Monotherapy: Five dose levels of M108 will be tested according to an accelerated titration method followed by a conventional 3 + 3 study design. Combined with chemotherapy: Three dose levels of M108 will be tested by a conventional 3 + 3 study design. The dose-limiting toxicity (DLT) will be assessed from the first administration to the end of the first cycle (21 days).

    Drug: M108

  • Experimental
    Dose Expansion Cohort

    Once the effective dose has been determined, 1\~2 expansion cohorts will be opened to evaluate the efficacy and safety of the selected dose.

    Drug: M108

Interventions

  • DrugM108

    Monotherapy: Accelerated titration method, IV infusion Q3W; Conventional 3 + 3 study design, IV infusion Q3W. (21-day cycles) Combined with chemotherapy: Conventional 3 + 3 study design, IV infusion Q3W. (21-day cycles)

    Also known as: Chemotherapy

  • DrugM108

    IV infusion Q3W. (21-day cycles)

    Also known as: Chemotherapy.

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events

    defined by the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE V5.0)

    Time frame: From enrollment until 28+7 days after the last dose

  2. Maximum Tolerated Dose

    MTD

    Time frame: 21 days

Secondary outcomes

  1. Maximum measured plasma concentration of M108

    Cmax

    Time frame: From enrollment until 28 days after the last dose

  2. Time to maximum plasma concentration of M108

    Tmax

    Time frame: From enrollment until 28 days after the last dose

  3. Half-life of M108

    T1/2

    Time frame: From enrollment until 28 days after the last dose

  4. Immunogenicity profile of M108

    Blood samples will be collected from subjects post treatment for assessment to detect the presence of anti-drug antibodies(ADA).

    Time frame: From enrollment until 28 days after the last dose

  5. Objective Response Rate

    ORR

    Time frame: From first dose to disease progression , death or end of study,an average of 1 year

  6. Progression free survival

    PFS

    Time frame: From first dose to disease progression , death or end of study,an average of 1 year

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2021 (actual). Primary completion is estimated for Jul 2024, 37 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2021
First posted
May 20, 2021
StartActual
Jun 11, 2021
Primary completionEst.
Jul 30, 2024
CompletionEst.
Dec 30, 2024
Last update
Nov 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04894825
Responsible party
Sponsor
First posted
May 20, 2021
Start date
Jun 11, 2021
Primary completion
Jul 30, 2024 (estimated)
Completion
Dec 30, 2024 (estimated)
Last update
Nov 27, 2023

Study contacts

Zhaoyu Jin, Ph.D
Contact
pr@futuregenbiopharm.com
010-60709130

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Terallethrin

Start the discussion